Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;31(34):5612-5619.
doi: 10.2174/0109298673268883231108062655.

The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS

Mengming Xia  1 , Ya-Nan Liu  2 , Jie Chen  2 , Ren-Ai Xu  2 , Gexin Dai  2
Affiliations

The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS

Mengming Xia et al. Curr Med Chem. 2024.

Abstract

Background: Tirabrutinib is an orally effective, approved, and highly selective second-generation Bruton's tyrosine kinase (BTK) inhibitor for the treatment of recurrent or refractory primary central nervous system lymphoma (PCNSL).

Objective: This study aimed to develop an ultra-high performance liquid chromatography- tandem mass spectrometry (UPLC-MS/MS) method for the determination of tirabrutinib concentration in rat plasma, where zanubrutinib was used as an internal standard (IS). This method was also applied to study whether tirabrutinib would interact with voriconazole, itraconazole, and fluconazole in rats, providing a reference value for clinical medication guidance.

Methods: In the current study, the organic solvent protein precipitation method was used to treat plasma samples, which is simple and reproducible. Tirabrutinib (m/z 455.32 → 320.21) and zanubrutinib (m/z 472.13 → 455.04) were separated on a Waters Acquity BEH C18 column (2.1 × 50 mm, 1.7 μm) and detected by multiple reaction monitoring (MRM) in positive ionization mode.

Results: The method showed good linearity in the range of 5-3000 ng/mL for tirabrutinib with the lower limit of quantification (LLOQ) of 5 ng/mL. The recovery and matrix effects were 85.7-91.0% and 102.0-113.3%, respectively. The accuracy, precision, stability, and carry-over effect were also acceptable. The method could also be used for determining the pharmacokinetic interaction of tirabrutinib in rats. The results showed AUC0→∞ of tirabrutinib to be increased by 139.3% and 83.9% in the presence of voriconazole and fluconazole, respectively, while itraconazole had little effect.

Conclusion: It is necessary to monitor the concentration of tirabrutinib in patients when it is combined with voriconazole and fluconazole to achieve a better therapeutic effect and reduce the risk of adverse reaction. Further research should be conducted in the future.

Keywords: BTK inhibitor; PCNSL.; Tirabrutinib; UPLC-MS/MS; drug-drug interaction; voriconazole.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Pal Singh S.; Dammeijer F.; Hendriks R.W.; Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 2018,17(1),57 - DOI - PubMed
    1. Liclican A.; Serafini L.; Xing W.; Czerwieniec G.; Steiner B.; Wang T.; Brendza K.M.; Lutz J.D.; Keegan K.S.; Ray A.S.; Schultz B.E.; Sakowicz R.; Feng J.Y.; Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton’s tyrosine kinase reveals differences in on : And off : Target inhibition. Biochim Biophys Acta, Gen Subj 2020,1864(4),129531 - DOI - PubMed
    1. Castillo J.J.; Treon S.P.; Davids M.S.; Inhibition of the bruton tyrosine kinase pathway in B-cell lymphoproliferative disorders. Cancer J 2016,22(1),34-39 - DOI - PubMed
    1. Küppers R.; Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005,5(4),251-262 - DOI - PubMed
    1. Liu X.J.; Xu-Liu ; Pang X.J.; -Ying Yuan X.; Yu G.X.; Li Y.R.; Guan Y.F.; Zhang Y.B.; Song J.; Zhang Q.R.; Zhang S.Y.; Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy. Bioorg Med Chem 2021,47,116358 - DOI - PubMed

LinkOut - more resources